Company Drug

Astellas’ XOSPATA Fails Phase III Primary Endpoint in Frontline AML – FLT3 Inhibitor Misses OS Benefit vs. Midostaurin

By Fineline Cube #Astellas Pharma #Cancer #Clinical trial results #TYO: 4503
Astellas' XOSPATA Fails Phase III Primary Endpoint in Frontline AML – FLT3 Inhibitor Misses OS Benefit vs. Midostaurin

Astellas Pharma Inc. (TYO: 4503) and the HOVON Foundation announced that the Phase III HOVON 156 / AMLSG 28-18 / PASHA study of XOSPATA (gilteritinib) failed to meet its primary endpoint of overall survival (OS) in newly diagnosed FLT3-mutation-positive (FLT3m+) acute myeloid leukemia (AML). While the study did not demonstrate superior OS versus the midostaurin-based regimen, gilteritinib showed comparable survival benefit with similar safety profiles, preserving its relapsed/refractory (R/R) positioning but limiting frontline expansion potential for the $400M+ revenue franchise.

Clinical Trial Results

EndpointXOSPATA (Gilteritinib)Midostaurin-Based RegimenOutcome
Primary: Overall Survival (OS)Not superiorStandard comparatorFailed to meet primary endpoint
OS ComparisonComparable benefit—Non-inferior but not superior
Safety: TEAEsSimilar incidenceMidostaurin armManageable toxicity profile
Safety: Grade ≥3 AEsSimilar rateMidostaurin armNo unexpected safety signals
Study PopulationNewly diagnosed FLT3m+ AML, intensive chemo-eligible—High-unmet-need population

Study Design:

  • Name: HOVON 156 / AMLSG 28-18 / PASHA
  • Phase: III
  • Comparator: Midostaurin (first-generation FLT3 inhibitor) + intensive chemotherapy
  • Sponsors: Astellas Pharma + HOVON Foundation (Dutch cooperative group)

Drug Profile & Approved Indications

AttributeGilteritinib (XOSPATA) Specification
Drug ClassSecond-generation FLT3 tyrosine kinase inhibitor
Target CoverageFLT3-ITD (internal tandem duplication) + FLT3-TKD (tyrosine kinase domain) mutations
MechanismInhibits FLT3 signaling driving leukemic cell proliferation and survival
Approved IndicationsRelapsed or refractory FLT3+ AML (U.S., Japan, China, EU, other regions)
Development PartnerKotobuki Pharmaceutical Co., Ltd. (co-development)
Global RightsAstellas (exclusive development, commercialization, manufacturing)

Strategic Implications

FactorImpact
Frontline Expansion BlockedXOSPATA remains R/R-only; midostaurin retains 1L FLT3m+ AML standard-of-care position
Revenue ForecastPeak sales estimates reduced; R/R market saturation limits growth trajectory
Competitive DynamicsQuizartinib (Daiichi Sankyo) frontline Phase III ongoing; crenolanib (Arog) development continues
Safety PreservationComparable toxicity to midostaurin supports continued R/R use; no black box warning risk
Label StrategyPotential exploratory endpoints (CR rate, MRD negativity) may support niche positioning

Competitive Landscape

CompetitorProductMechanismFrontline StatusPost-Trial Implication
NovartisRydapt (midostaurin)Multi-kinase (FLT3, PKC, etc.)Approved (1L FLT3m+ AML)Retains frontline standard; generic pressure 2027+
Daiichi SankyoVanflyta (quizartinib)FLT3-ITD selectivePhase III (QuANTUM-First)Potential frontline entrant if OS benefit demonstrated
ArogCrenolanibPan-FLT3 (ITD + TKD)Phase IIIContinued development; 2nd-gen positioning
AstellasXOSPATAFLT3-ITD + TKDR/R approved; 1L failedDefensive R/R franchise; combination studies may continue

Forward-Looking Considerations

  • Combination Strategies: XOSPATA + venetoclax + azacitidine (non-intensive) studies ongoing for unfit patients
  • MRD-Driven Trials: Exploratory endpoints may support adjuvant or maintenance positioning post-remission
  • Quizartinib Threat: If QuANTUM-First succeeds, XOSPATA R/R share at risk due to physician familiarity with competitor
  • Generic Timeline: Midostaurin patent expiry 2027 may open frontline market for cost-effective alternatives

Forward‑Looking Statements
This brief contains forward‑looking statements regarding XOSPATA’s commercial trajectory, competitive positioning, and pipeline adjustments following the Phase III failure. Actual results may differ due to competitive dynamics with quizartinib, combination study outcomes, and pricing pressures in the R/R AML market.-Fineline Info & Tech

Related Post

Company Drug

Pfizer’s Tilrekimig Hits Phase 2 Primary Endpoint – IL-4/IL-13/TSLP Trispecific Shows 52% EASI-75 Response in Atopic Dermatitis

Fineline Cube
Company Drug

FDA Accepts ENHERTU sBLA with Priority Review – HER2 ADC Seeks Early Breast Cancer Approval with 53% Recurrence Risk Reduction

Fineline Cube
Company Drug

J&J Files TECVAYLI Line Extension with EMA – BCMA Bispecific Seeks Earlier Use in Second-Line Multiple Myeloma

Fineline Cube

You Missed

Company Drug

Pfizer’s Tilrekimig Hits Phase 2 Primary Endpoint – IL-4/IL-13/TSLP Trispecific Shows 52% EASI-75 Response in Atopic Dermatitis

Company Drug

FDA Accepts ENHERTU sBLA with Priority Review – HER2 ADC Seeks Early Breast Cancer Approval with 53% Recurrence Risk Reduction

Company Drug

J&J Files TECVAYLI Line Extension with EMA – BCMA Bispecific Seeks Earlier Use in Second-Line Multiple Myeloma

Company Drug

HighTide Therapeutics’ HTD1801 NDA Accepted by NMPA – First-in-Class AMPK/NLRP3 Dual-Target Drug for Type 2 Diabetes